Consensus statement on the use of Alzheimer’s disease biomarkers and anti-amyloid therapies in Hong Kong
Year: 2026
Type: article
Abstract: Alzheimer's disease (AD) is the most common aetiology of cognitive impairment worldwide and in Hong Kong. There have been rapid advances in the use of biomarkers for the diagnosis of AD and in the availability of anti-amyloid therapies (AAT) to slow cognitive and functional decline. At present, there is no consensus in Hong Kong regarding the application of AD biomarkers or the use of AAT. A multidisciplinary group of 20 medical specialists from five professional societies discussed issues related to the application of biomarkers for the diagnosis of AD pathology and the use of AAT, and reviewed the evidence in the context of local experience to inform recommendations. A modified Delphi approach was adopted to finalise the recommendations. Consensus was defined as ≥75% agreement on a 9-point Likert scale among panellists. The panel finalised 26 consensus statements addressing the use of AD biomarkers, including neuroimaging and fluid biomarkers, as well as the use of AAT, including inclusion criteria, serial neuroimaging monitoring during treatment, and management of infusion reactions. These recommendations are relevant to the Hong Kong healthcare setting and may serve as guidance for doctors across specialties to facilitate appropriate management of AD.
Source: Hong Kong Medical Journal
DOI: 10.12809/hkmj2514198
Institutions: Tuen Mun Hospital, Queen Mary Hospital, Chinese University of Hong Kong, Kwong Wah Hospital, University of Hong Kong, Hong Kong Baptist Hospital, Prince of Wales Hospital, Prince of Wales Hospital, Hong Kong Association of Registered Tour Co-ordinators, Hong Kong University of Science and Technology, Tung Wah Eastern Hospital
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7153880017
FWCI:
Cites:
Cited by:
Related to: